On Wednesday, October 1, 2025, the UK-US landmark deal was announced on the government website.
Tens of thousands of NHS patients will benefit from a landmark UK-US trade deal that secures access to vital medicines, with zero tariffs on pharmaceuticals to the US.
This agreement is part of the UK-US Economic Prosperity Deal, affirming the UK’s position within life sciences.
The deal promotes significant investments leading to thousands of jobs while bolstering pharmaceutical industry confidence.
The government plans a 25% increase in funding for innovative treatments, allowing for quicker approval of drugs that deliver significant health benefits.
The deal also ensures early access to new medicines for UK patients and enhances the UK’s ability to attract global life sciences investment, fostering a supportive environment for research and development.
It aligns with the government’s 10 Year Health Plan and emphasizes the importance of a thriving life sciences sector for improving health outcomes in the UK.
